Genotype-guided warfarin therapy: Still of only questionable value two decades on

Area of Science:

• Pharmacogenetics
• Clinical Pharmacology
• Genetics

Background:

• Clinical studies on genotype-guided warfarin dosing have yielded conflicting results, hindering widespread implementation.
• Pharmacogenetic studies often lack robust methodologies and fail to account for multifactorial influences on warfarin response.

Purpose of the Study:

• To critically re-evaluate key warfarin pharmacogenetic studies and identify reasons for the limited clinical implementation of genotype-guided dosing.
• To assess the validity of claims regarding the benefits of CYP2C9/VKORC1 genotyping for warfarin therapy.

Main Methods:

• A critical analysis of major, widely-cited warfarin pharmacogenetic studies and recent meta-analyses.
• Identification of methodological concerns and limitations in existing research.

Main Results:

• Significant variations in study designs, outcome measures, and limited genotyping of CYP2C9/VKORC1 alleles were observed.
• Claims of genotyping benefits rely heavily on time-labile INR parameters, with no significant impact on bleeding or thromboembolic events.
• Factors like phenoconversion and non-adherence were inadequately addressed, and studies lacked power to assess indication-specific benefits.

Conclusions:

• Over-optimistic expectations of eliminating warfarin dose variability solely through CYP2C9/VKORC1 genotyping, as non-genetic factors account for 60% of variability.
• Real-world studies often do not corroborate trial-based claims of clinical benefit, suggesting cost-ineffectiveness.
• Resources may be better allocated to pharmacogenetic research with greater potential clinical relevance.